

Bovine stem cells: methodology and applications

Aleena A. Saidova^{1,2*}

¹Biological Faculty, M.V. Lomonosov Moscow State University, Moscow, Russia, 119991

²Center of Experimental Embryology and Reproductive Biotechnology, Moscow, Russia, 127422

Received: 18 December, 2018; Accepted: 29 December, 2018; Published: 31 December, 2018

*Corresponding author: Aleena Saidova, Biological Faculty, M.V. Lomonosov Moscow State University, Moscow, Russia, 119991, Tel: +7 (916) 5948383; E-mail: saidova@mail.bio.msu.ru

Abstract

Different types of stem cells have been extensively explored and described in human and rodents, but not in the domestic ungulates. Large animal models provide an essential opportunity to expand our knowledge in developmental biology and have significant advantages when modeling the long-term regenerative therapy, and disease-specific conditions. Moreover, transgenic animals with desired characteristics could be generated from modified pluripotent stem cells with novel reproduction approaches. Tissue and cell engineering of disease-resistant cattle could have an outstanding impact on the world economy. However, the validation and establishment of bovine stem cell lines have not received the deserved attention. This review provides systematic information on the special considerations for the establishment of the bovine stem cell lines and covers the different applications of bovine stem cells in regenerative therapy, genetic engineering, and translational medicine.

Keywords: Bovine Stem Cells; bESC; iPSC; Translational Medicine;

Introduction

Cows and cattle are of outstanding importance among all the ungulates for the livestock industry, being a source of meat and dairy products [1]. Full sequencing of cattle genome in 2009 opened new perspectives for the gene editing and transgenic modifications to produce a genetically superior cattle [2]. Examples of successful transgenesis include and expression of proteins with biomedically essential properties like human α -lactalbumin in milk and tissue engineering of mastitis-resistant cattle [3-5]. Technical limitations in the field of transgenic animals research include the limited lifespan of primary cell lines, as most of the cells (including fetal bovine fibroblasts) transfer to the senescent state in about 50 rounds of replication, that dramatically decreases the efficiency of the Somatic Cell Nuclear Transfer (SCNT), which was the first technology that was employed to obtain genetically modified animals [6]. Development of new methodological approaches led to the derivation of Embryonic Stem Cells (ESC) and Induced Pluripotent Stem Cells (iPSC) which not only provide the fundamental clues to the understanding of the pluripotency program in livestock species but also demonstrate a tremendous potential for producing cattle with the desired genetic properties through genomic selection and/or genome editing as well as for in vitro breeding schemes through genomic selection, germ cell differentiation, and in vitro fertilization.

To fit the criteria of stemness, stem cells have to pass the functional tests including the embryoid bodies formation in vitro and the ability to form teratomas in immunodeficient mice [7]. The molecular signature of stem cells for most mammalian species include a typical pattern of pluripotency markers Oct4, Sox2, Rex1 and Nanog [8]. Another set of stemness markers often used in fundamental studies is stage-specific embryonic antigens (SSEAs) that include SSEA-1, SSEA-3, and SSEA-4. Expression of SSEA molecules strongly depends on the source of stem cells and varies between species, as human ESC express SSEA-3 and SSEA-4, while mouse stem cells usually express SSEA-1 only [9,10]. The species-specific differences should also be taken into account for the development of culturing conditions and maintenance requirements. Despite that all stemness tests have been developed mainly for human and rodent cells and experimental models, the same molecular markers were applied to describe different types of stem cells from ungulates. Regardless of the significant and extensive efforts, the validation of stem cell lines from cattle has not been accomplished.

The current review focuses on the basic concepts relating to the fundamental biology of bovine stem cells and describes the state of art for derivation of ESC and iPSC in cattle, including successful and unsuccessful efforts to establish and validate viable bSC cell lines together with specific requirements and culturing conditions for the maintenance of these cells in undifferentiated state. Another critical issue of the review is the translation of bovine in vitro models to clinical in vivo assays.

Bovine Mesenchymal Stem Cells

Stem cells are defined as a specific group of cells with self-renewing capacities that remain undifferentiated in embryos, fetuses, and adults. The highest order of the developmental potential is totipotency which is an intrinsic property of a zygote (Figure 1). This means that zygote can generate all cell types inside the embryo and also contribute to the extraembryonic tissues [11]. The sequential step of development is the pluripotent cells that include embryonic germ cells (EGCs), cells from the inner mass of the blastocyst (ICMCs), embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs). Embryonic stem cells are the ancestors of the pluripotent cells from pre-implantation embryos, while induced pluripotent stem cells can be reprogrammed from the adult somatic cells. Both cell types are

pluripotent and possess the capacity to differentiate into most cells excluding the trophoblast and extra embryonic endoderm.

The more lineage-restricted cells are defined as adult stem cells. Among them, mesenchymal stem cells (MSC) (or mesenchymal stromal cells) require more special consideration. The most common and classical source for MSC is bone marrow [12]. However, MSCs can also be derived from the adipose tissue, peripheral blood, skin, and lungs [13-15].

Despite a heterogeneity and poor phenotypic description of MSC population, these cells are defined as pluripotent and differentiate not only to multiple types of connective tissue but also demonstrate a cross-over into non-mesodermal cell lineages [16]. In that respect, MSC can be considered as an ethically acceptable alternative to ESC for regenerative medicine, as reported for the regeneration of bone, cartilage and spinal cord injuries for different model organisms [17-23]. In the veterinary clinic, MSCs are introduced into protocols to treat lameness in dogs and horses, however, taken into account the facts above this technique should be practiced more carefully [24-26].

The primary source for isolation of the bovine MSC (bMSC) is umbilical cord and bone marrow [27-29]. Similar to other organisms, the characteristic phenotype of bMSC is CD29+/CD73+/CD90+/CD105+, while the negative phenotype markers have not been reported. bMSCs *in vitro* demonstrate a fibroblast-like morphology and can differentiate into three classic mesenchymal lineages: chondrogenic (with an expression of collagen II and aggrecan), adipogenic (with an expression of PRAR- γ and ALP) and osteogenic (with an expression of collagen I) [27, 30-32]. Most studies on bMSC were performed on hydrogels or in pellets and evaluated the characteristics of chondrogenic bMSC differentiation, as bMSC easily enter the chondrogenic differentiation in the absence of growth factors, which might be a natural characteristic of these cells [30]. However, cell pellet or monolayer is not sufficient for regenerative purposes, as bMSCs that can grow in a 3D assay require the presence of TGF β 1 and start to express collagen II only after medium optimization [29, 31]. Although the bMSC demonstrate the spontaneous chondrogenic differentiation, their use in regenerative therapy is limited due to the low quantities of extracellular matrix components that chondroblasts express after differentiation and the assay protocols require further optimization.

Bovine embryonic stem cells

The first ESC lines were generated from the mouse blastocysts [33-34]. Such cells formed a sphere-like colonies, LIF and FBS were reported as first supplemental factors for the propagation of these cells [35]. Later it was reported that serum could be replaced with BMP4, whereas inhibitors of GSK3 or MAP/ERK signaling can be used as LIF surrogates [36,37]. These colonies can be trypsinized and clonally propagated; they can also colonize ICM in the embryos to form chimeras and be introduced as a part of embryonic germ cells [38].

The pig was the first large animal model used for ESC derivation due to the large size and immunological similarity to

human tissues [39]. Extensive efforts have been made to obtain porcine ESC lines from different sources, including outgrowths of the epiblast and embryonic ICM, parthenogenetic embryos and embryos obtained by SNT. Although all the lines demonstrated some pluripotency features, all of them with a few exceptions failed to survive at extended passages [40-42]. Most of them also failed to expand into teratomas in SCID/nude mice and could not contribute to chimeras, thus confirming the inability, to match the pluripotency criteria.

Porcine cell lines most capable of forming teratomas were derived from the parthenogenetic embryos, in this case, basal ESC medium with FBS contained three critical supplemental factors, namely LIF, FGF2, and KITLG [42]. These data demonstrated that the primary culture conditions suitable for human and mouse embryos could be insufficient for other ESC and that a unique combination of growth factors and supplements should be validated for each animal model. Some data showed a promising effect of LIF and FGF2 together; the addition of GSK3 β and MEK inhibitors (so-called 2i medium, initially modified for rat ESC) was also described as a putative strategy [40].

The first bovine ESC were isolated as primary cell lines from ICM cells and could retain the normal karyotype for a few passages [43]. The next step to create the ESC culture was the development of suspension system that allowed to culture cells in low concentrations [43]. ES-like cells produced from the cultured blastocysts were used as donors for NT, and this method allowed to generate calves at a comparable to SCNT frequencies [44]. An idea to isolate cells from morulae and blastocysts allowed to culture viable cells for more than 50 passages. Stice, et al. [45] employed these cells as donors for nuclear transfer and managed to obtain embryos ready for implantation, albeit all the embryos were unable after 60 days due to the placental defects. Iwasaki et al. [46] made an advance with the isolation of viable and stable bESC line from the ICM. They reported that ES-like cells from the ICM of *in vitro* embryos could be aggregated with tetraploid bovine embryos in a feeder-free system. 36% of these embryos passed the blastocyst stage, and 15% were implanted to recipient cows. Two of six calves were chimeric in the hair roots and liver, though all of them died shortly after birth. First, a long-term line of bovine ESC that was viable for about 258 days was obtained on a mixed feeder layer consisting of bovine and mouse fibroblasts selected and purified for 30 passages. Unfortunately, ES cell morphology, in this case, was confirmed only by alkaline phosphatase staining and embryoid bodies formation tests. In 2001 Mitalipova et al. described the Z2 line of bESC that was stable for more than 150 passages and proved that, as for murine ESC, bESC cells were positive for SSEA-1, SSEA-3, SSEA-4, c-kit and passed EB formation test but failed to form teratomas in nude/SCID mice [47]. Subsequent studies reported the SSEA-1, SSEA-4, Oct-4 and Nanog-positive bESC [48]. The next generation of methodology efforts focused on modification of culturing conditions and isolation of primary cells from the alternative sources. Verma et al. reported the efficient isolation of eight parthenogenetic cell lines (bpESC) from 15 *in vitro* parthenotes [49]. Five of these cell lines were viable for more than 140 days

and expressed for Oct4, Nanog, SSEA-1, and SSEA-4 (confirmed both on mRNA and protein level), bpESC could form embryoid bodies and differentiated into three germ layers. Epigenetic regulation also turned out to be an important tool in optimizing the bESC colonies derivation. According to the murine assays, epigenetic modification of ES-like cells with decitabine (5'-aza-2'-deoxycytidine) increased the number of ES-like colonies [50]. Using the pressed zona pellucida-free blastocysts and embryonic explants treated with five μ M of 5'-azacytidine Lim et al. demonstrated the 18-fold increased efficiency of bESC isolation [51]. Importantly, these bESC-like cells passed all the pluripotency tests including teratoma formation in nude/SCID mice.

The best-suggested combination for the bovine ESC was FGF2, LIF and in FBS-containing medium (20) and 2i medium that had the same effect as for pigs [52]. It has also been stated that supplement of 2i medium to embryos between the morula and blastocyst stages led to the subsequent recovery of all cell lines from the blastocysts, although all of them demonstrated a limited proliferative capacity [53]. Gong et al. successfully applied a protocol of the enzymatic dissociation to maintain the ESC-like morphology during culturing, but these cells were viable for only ten passages [54]. The above summary suggests that well-established and genuinely pluripotent cell lines do not exist for bovine ESC and that protocols suitable for human and rodents should be revised and expanded. Bogliotti et al. applied a custom TeSR1 base medium (growth factor-free) supplemented with FGF2 and IWR1 (CTFR), for the derivation of bESCs [55]. CTFR culture conditions allowed to obtain pluripotent ESC that could be established by three or four weeks after ICM plating and remained stable for more than 50 passages. These cells demonstrated stable karyotype and expressed the pluripotency markers SOX2 and POU5F1 (OCT4) and passed the teratoma assay test. Moreover, bESCs displayed transcriptional and epigenetic characteristics of primed pluripotency. bESC cultured in CTFR were also good donors for the somatic nuclear transfer that opens good perspectives for the genome editing studies. Another critical consideration for culturing the bESC is regulation of pluripotency-related genes in bovine inner cell mass (ICM) explants. Pant et al. showed that inhibition of the BMP4 pathway with noggin successfully up regulated the expression of Nanog in ICM explants [56]. Thus the evaluation of in vitro conditions to keep cells in an undifferentiated state for long passages should be the next step for bESC maintenance.

Bovine induced pluripotent stem cells

The iPSC technology in which embryonic or adult somatic cells gain the pluripotency features using gene reprogramming was first introduced for mouse [57]. The iPSC technology has been successfully applied to the full range of domestic animals [58-61].

Several efforts have been made for iPSC generation from cattle and cows. In most cases, transgene delivery methods included retroviral and lentiviral vectors. However, the use of viral transfection imposes the possibility of transgene expression after

the completion of reprogramming and can potentially escalate the possibility of mutation. To avoid the non-desirable effects, different groups applied the non-integrating plasmid vectors and transposons [62-66]. As for ESC, the primary trigger for colony derivation and cell reprogramming was the media composition and the vital supplemental factors. In the presence of LIF on its own or in combination with BMP4 or 2i medium, naïve cell phenotype was obtained [62-64, 67]. Reprogramming of the bovine fibroblasts with transposon delivery of 6 genes in a medium with FGF2 and LIF was also successful. However, the transgenes remained transcriptionally active after the reprogramming [65]. In 2016 Malaver-Ortega et al. showed that LIF alone or in combination with bFGF increased the mRNA expression of Oct4 and REX1 genes, while bFGF alone led to a dramatic decrease in expression of the same genes [68]. The results with GSK3/MEK inhibitors were also promising: 6-bromoindirubin-3-oxime and Sc1 inhibitors alone or in combination with 5-AzaC induced significantly higher levels of expression of endogenous REX1, OCT4, NANOG, and SOX2. Thus, the biPSC gene expression profile is malleable by modification of the cell culture conditions, and the culture conditions determined the differentiation capacities of iPSC. Transfection of biPSC with AID (activation-induced cytidine deaminase) also led to increased levels of OCT-3/4 and NANOG in biPSC due to the enhancement of DNA demethylation [69]. The novel approach to the derivation of biPSC was single cell cloning of bovine iPSCs generated by the introduction of piggyBac transposons with cloning the efficiency at 40%; these cells were able to passage not less than 50 passages after the enzymatic dissociation and fit all the iPSC criteria.

The gold standard of iPSC generation method employs the lentiviral or retroviral transduction of the necessary transcription factors into the target cells. However, the new non-integrating techniques that transduce target cells with replication-competent RNAs of the reprogramming factors are widely used and extensively developed [70]. Another novel methodology focuses on optimization of mRNA-based procedures, like the synthesis of self-replicating DNA that eliminates the step of repeated transfections [71]. Furthermore, certain chemical compounds can in some cases substitute the endogenous reprogramming transcription factors, though that expression of OCT4 usually an essential prerequisite [72-73]. Hou et al. were the first who showed a successful reprogramming of mouse somatic cells with a cocktail of seven small molecules and called these cells ciPSC (chemically induced PSC) [74]. Unfortunately, to date, there are no reports for reprogramming biPSC with more high-end methods like non-integrating viral or mRNA based, that is also fair for other farm species.

Moreover, the germline contribution potential was not confirmed for the majority of the biPSCs, so most of the biPSC cells in the studies should be termed as iPSC-like cells. To date, all the extensive efforts failed to obtain the biPSCs that can produce viable and fertile offspring due to the possible presence of exogenous transcription factors [75]. The problem of exogenous expression must be solved for the field to move on, and the possible perspectives are the optimization of culture conditions

that could be favourable for the activation of the endogenous signalling pathways, autologous feeder layers (that in turn raise a point of assay reproducibility) and possible synthesis or derivation of supplemental growth factors that are more specific for the target species (like bovine LIF instead of human or mouse LIF).

Translational Medicine and Bovine Stem Cells

Bovine model is an underestimated model for studying human diseases. Cattle, like all large animal models, can provide significant advantages when establishing the long-therapy approaches, and modeling the disease-specific conditions. The most critical applications of bovine models include cartilage repair, mammary gland regeneration and hereditary genetic diseases of the blood and immune system.

Cartilage

Because of poor regenerative capacities of the articular cartilage, this tissue is one of the central targets of regenerative therapy. Experimental assays on bovine models addressed the problems of osteoarthritis, cartilage degeneration, induced chondrogenesis, and cartilage aging. The latter has been described on a 3D cell culture of native bovine cartilage chondrocytes from fetal, juvenile and adult animals. In this system, adult chondrocytes demonstrated diminished collagen formation capacities and altered biochemical properties [28]. Likewise, fetal and juvenile MSCs in hydrogels for the same animals had a greater matrix and mechanical properties, confirming that donor age is one of the significant determinants of regenerative capacities both for chondrocytes and MSC. Steinert et al. demonstrated that the differentiation of MSC into chondrocytes could be enhanced by transduction BMP-2, IGF1, and TGF β 1 in the adenoviral system [76]. Simultaneous expression of three chondrogenic proteins in MSC resulted in larger cell aggregates and a higher level of cartilage-specific proteoglycans and collagen, indicating that gene-induced chondrogenesis may be a basis for stem-cell-based therapy for cartilage repair. Another approach to cell-based therapy is derivation and cloning of chondroprogenitor from native immature cartilage. Individual cells were isolated from bovine immature metacarpalphalangeal joints by differential adhesion to fibronectin. Cloned colonies of these cells had transcription profile similar to MSC and successfully differentiated into cartilage in 3D pellet cultures, so critical determinants of the progenitor phenotype could be maintained in in vitro system [77]. The next problem of chondrogenesis assays was that MSC constructs for cartilage repair could not achieve the functional properties of the native tissue due to possible absence of additional stimuli. It was natural to assume that mechanical stimulation could be the optimal strategy to overcome the functional limitations of in vitro assays. First studies on human and rabbit MSCs showed that dynamic compression enhanced the expression of collagen II and aggrecan and that presence of TGF β influenced this process [78-79]. Huang et al. applied long-term compressive loading to bMSC-seeded scaffolds and evaluated the mechanical properties of the constructs after six weeks [79]. Mechanical loading initiated shortly after induction of chondrogenesis and

matrix aggregation improved the mechanistic properties of differentiated chondrocytes and expression of aggrecan I and collagen type II in the presence of TGF β .

One more strategy to enhance the regenerative potential of MSC was to mimic the embryonic processes that occur during the development of healthy cartilage. Allon et al. designed the bilaminar cell pellet consisting of bMSC in a shell of nucleus pulposus cells [80]. In stress or inflammation conditions, this bilaminar cell pellet employed inductive mechanisms from development to trigger differentiation in the absence of growth factors, that seems to be a definite advantage of this model. Another co-culture system of neonatal chondrocytes with adipose-derived stem cells in 3D hydrogels demonstrated the synergy that correlated with the cell density increase and resulted in the formation of large cartilage nodules; this work raised the potential of stem cells to catalyze tissue formation via paracrine signaling [81]. The next step that pointed towards the clinical translation of cartilage repair on bovine models was to overcome the potential problems with integration of in vitro constructs into in vivo models of cartilage injury. Erickson et al. proposed to use bMSC in encapsulated methacrylated hyaluronic acid hydrogels that were precultured during four weeks before implantation, and, like in case of dynamic loading, showed that initial chondrogenesis before implantation allows avoiding the undesirable effects of environmental stress in vivo [28].

Mammary gland

A shared hierarchy of human and bovine mammary glands provides evidence of common mechanisms regulating the maintenance and differentiation of mammary stem cells from human and cattle [82]. Martignani et al. reported the in vitro colony formation assay of bovine mammary stem cells that lack aldehyde dehydrogenase activity and resembled the luminal epithelial stem cell through the differentiation [82]. The regenerated structures recapitulated the organization of bovine mammary tissue. Among the complex and heterogenic cell types in the mammary gland, epithelial and myoepithelial progenitors are of particular interest for the regeneration of the vascular network in this tissue.

In this direction, Rauner et al. tried to establish in-vivo expansion of bovine mammary stem cells using a xanthosine administration to induce the proliferation of mammary stem cells [83].

The outputs of this research will have a significant impact on several aspects of mastitis and will improve current treatment regimens, but to date, the experimental assays with iPSC and MSC differentiation in the mammary gland are still at the beginning.

Genetic diseases of immune and blood cells

Several human genetic diseases have counterparts in large animal models. In most cases, bovine models contain the mutation of the same gene or employ the similar pathogenesis, and thus can serve as valuable preclinical models for testing the cell transplantation or gene therapy approaches.

Bovine Model of Leukocyte Adhesion Deficiency Type I (BLAD) was first described in a Holstein's calf with marked neutrophilia and impaired neutrophil function. BLAD calves have pneumonia, enteritis, periodontitis, and altered wound healing. The primary defect in BLAD leukocytes, as in human, lies in a deficiency of $\beta 2$ integrin subunit of CD18 due to the point mutation in a highly conserved region of the CD18 gene [84]. Gene therapy approach using SCNT using bone marrow cells from a healthy cow allowed to obtain 0.3-0.5% of donor neutrophils in the peripheral blood of the calf in a year after therapy [85]. The heifer also demonstrated a sustainable clinical improvement in 28 months with increased levels of CD18 positive donor leukocytes [86].

Chediak-Higashi Syndrome (CHS) is an autosomal recessive disorder that affects nervous, and the immune system is considered to be a lysosomal disease [87]. An animal model for CHS include Hereford, and Japanese black cattle. Japanese black cattle have abnormal giant granules in leukocytes, decrease the number of granules in platelets and bleeding from minor trauma [88-89]. CHS in Hereford cattle and Brangus cattle with chronic infections, and a marked susceptibility to infection, petechial hemorrhaging, pulmonary abscesses, and pneumonia demonstrated a more severe phenotype compared to Japanese black cattle. CHS in Brangus cattle had a similar phenotype to that of Hereford cattle [90]. The severe CHS phenotype contrasts with the disease in Japanese black cattle, which was moderate and rarely fatal. It is possible that the causative mutation in CHS-affected Brangus and Hereford cattle is different from that in

Japanese black cattle. Gene therapy and stem cell-based approach have been not attempted on these models due to the large size of the affected gene, but a novel vector packaging and delivery models may overcome these difficulties.

Conclusions and future perspectives

Though the indisputable importance in agriculture and biotechnology, bovine stem cells and have not received the proper attention as a model for preclinical research. Cattle represent a valuable model for the development of cell-based treatments before introducing them to the clinical practice. In this review, we showed that bovine stem cells from different origins require a unique set of culturing and maintenance conditions and possess a phenotype that does not correlate with human or rodent stem cells. At the same time, applications of bovine stem cells in regenerative therapy, and gene editing therapy can be a useful translational preclinical model. It is necessary to develop the exact phenotype criteria to manipulate bovine stem cells in clinical practice. Bovine stem cell therapy offers new perspectives for exploitation and exploration in livestock industry research.

Acknowledgments

The author has received no funding for this manuscript.

Author contributions

Aleena A. Saidova designed, drafted and critically revised the manuscript




Figure 1: Bovine stem cells with decreasing potencies are derived from the animals at different developmental stages. The only exception is induced pluripotent stem cells (iPSCs) that are derived from adult animals.

References

- Niemann H, Kuhla B, Flachowsky G. Perspectives for feed-efficient animal production. *Journal of animal science*. 2011; 89 (12):4344-63.
- Elsik CG, Tellam RL, Worley KC, Gibbs R A, Muzny DM, Weinstock GM, et al. The genome sequence of taurine cattle: a window to ruminant biology and evolution. *Science*. 2009; 324 (5926):522-528. doi: 10.1126/science.1169588
- Yang B, Wang J, Tang B, Liu Y, Guo C, Yang P, et al. Characterization of bioactive recombinant human lysozyme expressed in milk of cloned transgenic cattle. *PLoS one*. 2011;6 (3):e17593. doi: 10.1371/journal.pone.0017593
- Wang J, Yang P, Tang B, Sun X, Zhang R, Guo C, et al. Expression and characterization of bioactive recombinant human alpha-lactalbumin in the milk of transgenic cloned cows. *Journal of dairy science*. 2008;91(12):4466-4476. doi: 10.3168/jds.2008-1189
- Donovan DM, Kerr DE, Wall RJ. Engineering disease resistant cattle. *Transgenic research*. 2005;14 (5):563-567. doi: 10.1007/s11248-005-0670-8
- Campbell KH, McWhir J, Ritchie WA, Wilmut I. Sheep cloned by nuclear transfer from a cultured cell line. *Nature*. 1996;380 (6569):64-66. DOI: 10.1038/380064a0
- Pera MF, Reubinoff B, Trounson A. Human embryonic stem cells. *Journal of cell science*. 2000;113, 5-10.
- Xie D, Chen CC, Ptaszek LM, Xiao S, Cao X, Fang F, et al. Rewirable gene regulatory networks in the preimplantation embryonic development of three mammalian species. *Genome research*. 2010;20 (6):804-815. doi: 10.1101/gr.100594.109
- Trusler O, Huang Z, Goodwin J, Laslett AL. Cell surface markers for the identification and study of human naive pluripotent stem cells. *Stem cell research*. 2018;26:36-43. doi: 10.1016/j.scr.2017.11.017
- Isobe K, Cheng Z, Ito S, Nishio N. Aging in the mouse and perspectives of rejuvenation through induced pluripotent stem cells (iPSCs). *Results and problems in cell differentiation*. 2012;55:413-427.
- Mitalipov S, Wolf D. Totipotency, pluripotency and nuclear reprogramming. *Advances in biochemicaengineering/biotechnology*. 2009;114:185-99. doi: 10.1007/10_2008_45
- Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. *Cytotherapy*. 2006; 8 (4):315-317. DOI: 10.1080/14653240600855905
- Pierantozzi E, Gava B, Manini I, Roviello F, Marotta G, Chiavarelli M, et al. Pluripotency regulators in human mesenchymal stem cells: expression of NANOG but not of OCT-4 and SOX-2. *Stem cells and development*. 2011;20 (5):915-23. doi: 10.1089/scd.2010.0353
- Riekstina U, Cakstina I, Parfejevs V, Hoogduijn M, Jankovskis G, Muiznieks I, et al. Embryonic stem cell marker expression pattern in human mesenchymal stem cells derived from bone marrow, adipose tissue, heart and dermis. *Stem cell reviews*. 2009;5 (4):378-86. doi: 10.1007/s12015-009-9094-9
- Zvaifler NJ, Marinova-Mutafchieva L, Adams G, Edwards CJ, Moss J, Burger J, et al. Mesenchymal precursor cells in the blood of normal individuals. *Arthritis research*. 2000; 2 (6):477-88. doi: 10.1186/ar130
- Uccelli A, Moretta L, Pistoia V. Mesenchymal stem cells in health and disease. *Nature reviews Immunology*. 2008;8 (9):726-736. doi: 10.1038/nri2395
- Porada CD, Zanjani ED, Almeida-Porad G. Adult mesenchymal stem cells: a pluripotent population with multiple applications. *Current stem cell research & therapy*. 2006;1(3):365-369.
- Pittenger MF, Martin BJ. Mesenchymal stem cells and their potential as cardiac therapeutics. *Circulation research*. 2004;95(1):9-20. doi: 10.1161/01.RES.0000135902.99383.6f
- Jiang Y, Jahagirdar BN, Reinhardt RL, Schwartz RE, Keene CD, Ortiz-Gonzalez XR, et al. Pluripotency of mesenchymal stem cells derived from adult marrow. *Nature*. 2002;418(6893):41-49. doi:10.1038/nature00870
- Dai KR, Xu XL, Tang TT, Zhu ZA, Yu CF, Lou JR, et al. Repairing of goat tibial bone defects with BMP-2 gene-modified tissue-engineered bone. *Calcified tissue international*. 2005;77 (1):55-61. doi: 10.1007/s00223-004-0095-z
- Jang BJ, Byeon YE, Lim JH, Ryu HH, Kim WH, Koyama Y, et al. Implantation of canine umbilical cord blood-derived mesenchymal stem cells mixed with beta-tricalcium phosphate enhances osteogenesis in bone defect model dogs. *Journal of veterinary science*. 2008;9 (4):387-93.
- Lee KB, Hui JH, Song IC, Ardany L, Lee EH. Injectable mesenchymal stem cell therapy for large cartilage defects: a porcine model. *Stem cells*. 2007;25 (11):2964-71. doi: 10.1634/stemcells.2006-0311
- Lim JH, Byeon YE, Ryu HH, Jeong YH, Lee YW, Kim WH, et al. Transplantation of canine umbilical cord blood-derived mesenchymal stem cells in experimentally induced spinal cord injured dogs. *Journal of veterinary science*. 2007;8 (3):275-282.
- Black LL, Gaynor J, Adams C, Dhupa S, Sams AE, Taylor R, et al. Effect of intraarticular injection of autologous adipose-derived mesenchymal stem and regenerative cells on clinical signs of chronic osteoarthritis of the elbow joint in dogs. *Veterinary therapeutics : research in applied veterinary medicine*. 2008;9 (3):192-200.
- Pacini S, Spinabella S, Trombi L, Fazzi R, Galimberti S, Dini F, et al. Suspension of bone marrow-derived undifferentiated mesenchymal stromal cells for repair of superficial digital flexor tendon in race horses. *Tissue engineering*. 2007;13 (12):2949-55. doi: 10.1089/ten.2007.0108
- Vilar JM, Batista M, Morales M, Santana A, Cuervo B, Rubio M, et al. Assessment of the effect of intraarticular injection of autologous adipose-derived mesenchymal stem cells in osteoarthritic dogs using a double blinded force platform analysis. *BMC veterinary research*. 2014; 10:143. doi: 10.1186/1746-6148-10-143
- Raoufi MF, Tajik P, Dehghan MM, Eini F, Barin A. Isolation and differentiation of mesenchymal stem cells from bovine umbilical cord blood. *Reproduction in domestic animals Zuchthygiene*. 2011;46 (1):95-99. doi: 10.1111/j.1439-0531.2010.01594.x

28. Erickson IE, van Veen SC, Sengupta S, Kestle SR, Mauck RL. Cartilage matrix formation by bovine mesenchymal stem cells in three-dimensional culture is age-dependent. *Clinical orthopaedics and related research*. 2011;469 (10):2744-2753. doi: 10.1007/s11999-011-1869-z
29. Bosnakovski D, Mizuno M, Kim G, Takagi S, Okumura M, Fujinaga T. Chondrogenic differentiation of bovine bone marrow mesenchymal stem cells (MSCs) in different hydrogels: influence of collagen type II extracellular matrix on MSC chondrogenesis. *Biotechnology and bioengineering*. 2006;93(6):1152-1163. doi: 10.1002/bit.20828
30. Bosnakovski D, Mizuno M, Kim G, Ishiguro T, Okumura M, Iwanaga T, et al. Chondrogenic differentiation of bovine bone marrow mesenchymal stem cells in pellet cultural system. *Experimental hematology*. 2004;32 (5):502-509. doi: 10.1016/j.exphem.2004.02.009
31. Bosnakovski D, Mizuno M, Kim G, Takagi S, Okumura M, Fujinaga T. Isolation and multilineage differentiation of bovine bone marrow mesenchymal stem cells. *Cell and tissue research*. 2005;319(2):243-253. DOI: 10.1007/s00441-004-1012-5
32. Cardoso TC, Ferrari HF, Garcia AF, Novais JB, Silva-Frade C, Ferrarezi MC, et al. Isolation and characterization of Wharton's jelly-derived multipotent mesenchymal stromal cells obtained from bovine umbilical cord and maintained in a defined serum-free three-dimensional system. *BMC biotechnology*. 2012;12:18.
33. Evans MJ, Kaufman MH. Establishment in culture of pluripotential cells from mouse embryos. *Nature*. 1981;292 (5819):154-156.
34. Martin GR. Isolation of a pluripotent cell line from early mouse embryos cultured in medium conditioned by teratocarcinoma stem cells. *Proceedings of the National Academy of Sciences of the United States of America*. 1981;78 (12):7634-8.
35. Williams RL, Hilton DJ, Pease S, Willson TA, Stewart CL, Gearing Dp, et al. Myeloid leukaemia inhibitory factor maintains the developmental potential of embryonic stem cells. *Nature*. 1988; 336 (6200):684-687. doi: 10.1038/336684a0
36. Ying QL, Nichols J, Chambers I, Smith A. BMP induction of Id proteins suppresses differentiation and sustains embryonic stem cell self-renewal in collaboration with STAT3. *Cell*. 2003;115 (3):281-292.
37. Ying QL, Wray J, Nichols J, Batlle-Morera L, Doble B, Woodgett J, et al. The ground state of embryonic stem cell self-renewal. *Nature*. 2008;453 (7194):519-523. doi: 10.1038/nature06968
38. Austin CP, Battey JF, Bradley A, Bucan M, Capecchi M, Collins FS, et al. The knockout mouse project. *Nature genetics*. 2004; 36 (9):921-924. doi: 10.1038/nature06968
39. Brevini TA, Antonini S, Cillo F, Crestan M, Gandolfi F. Porcine embryonic stem cells: Facts, challenges and hopes. *Theriogenology*. 2007;1;68:206-13. doi: 10.1016/j.theriogenology.2007.05.043
40. Haraguchi S, Kikuchi K, Nakai M, Tokunaga T. Establishment of self-renewing porcine embryonic stem cell-like cells by signal inhibition. *The Journal of reproduction and development*. 2012;58(6):707-716.
41. Kim S, Kim JH, Lee E, Jeong YW, Hossein MS, Park SM, et al. Establishment and characterization of embryonic stem-like cells from porcine somatic cell nuclear transfer blastocysts. *Zygote (Cambridge, England)*. 2010;18(2):93-101.
42. Brevini TA, Pennarossa G, Attanasio L, Vanelli A, Gasparini B, Gandolfi F. Culture conditions and signalling networks promoting the establishment of cell lines from parthenogenetic and biparental pig embryos. *Stem cell reviews*. 2010;6(3):484-495.
43. Gjorret JO, Maddox-Hyttel P. Attempts towards derivation and establishment of bovine embryonic stem cell-like cultures. *Reproduction, fertility, and development*. 2005;17(1-2):113-124.
44. Sims M, First NL. Production of calves by transfer of nuclei from cultured inner cell mass cells. *Proceedings of the National Academy of Sciences of the United States of America*. 1994;91(13):6143-6147.
45. Stice SL, Strelchenko NS, Keefer CL, Matthews L. Pluripotent bovine embryonic cell lines direct embryonic development following nuclear transfer. *Biology of reproduction*. 1996;54(1):100-110.
46. Iwasaki S, Campbell KH, Galli C, Akiyama K. Production of live calves derived from embryonic stem-like cells aggregated with tetraploid embryos. *Biology of reproduction*. 2000;62(2):470-475.
47. Mitalipova M, Beyhan Z, First NL. Pluripotency of bovine embryonic cell line derived from precompacting embryos. *Cloning*. 2001;3(2):59-67.
48. Cao S, Wang F, Chen Z, Liu Z, Mei C, Wu H, et al. Isolation and culture of primary bovine embryonic stem cell colonies by a novel method. *Journal of experimental zoology. Part A, Ecological genetics and physiology*. 2009;311A(5):368-376.
49. Pashaiasl M, Khodadadi K, Holland MK, Verma PJ. The efficient generation of cell lines from bovine parthenotes. *Cellular reprogramming*. 2010;12(5):571-579.
50. Kim C, Amano T, Park J, Carter MG, Tian X, Yang X. Improvement of embryonic stem cell line derivation efficiency with novel medium, glucose concentration, and epigenetic modifications. *Cloning and stem cells*. 2009;11(1):89-100.
51. Lim ML, Vassiliev I, Richings NM, Firsova AB, Zhang C, et al. A novel, efficient method to derive bovine and mouse embryonic stem cells with in vivo differentiation potential by treatment with 5-azacytidine. *Theriogenology*. 2011;76(1):133-142.
52. Verma V, Huang B, Kallingappa PK, Oback B. Dual kinase inhibition promotes pluripotency in finite bovine embryonic cell lines. *Stem cells and development*. 2013;22(11):1728-1742.
53. Ozawa M, Sakatani M, Hankowski KE, Terada N, Dobbs KB, Hansen PJ. Importance of culture conditions during the morula-to-blastocyst period on capacity of inner cell-mass cells of bovine blastocysts for establishment of self-renewing pluripotent cells. *Theriogenology*. 2012;78(6):1243-1251.e1-2.
54. Gong G, Roach ML, Jiang L, Yang X, Tian XC. Culture conditions and enzymatic passaging of bovine ESC-like cells. *Cellular reprogramming*. 2010;12(2):151-160.

55. Bogliotti YS, Wu J, Vilarino M, Okamura D, Soto DA, Zhong C, et al. Efficient derivation of stable primed pluripotent embryonic stem cells from bovine blastocysts. *Proceedings of the National Academy of Sciences of the United States of America*. 2018;115 (9):2090-2095.
56. Pant D, Keefer CL. Expression of pluripotency-related genes during bovine inner cell mass explant culture. *Cloning and stem cells*. 2009;11(3):355-365.
57. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. *Cell*. 2006;126(4):663-676.
58. Malaver-Ortega LF, Sumer H, Liu J, Verma PJ. The state of the art for pluripotent stem cells derivation in domestic ungulates. *Theriogenology*. 2012;78(8):1749-1762.
59. Goncalves NN, Ambrosio CE, Piedrahita JA. Stem cells and regenerative medicine in domestic and companion animals: a multispecies perspective. *Reproduction in domestic animals = Zuchthygiene*. 2014;49 Suppl 4:2-10.
60. Ezashi T, Telugu BP, Roberts RM. Induced pluripotent stem cells from pigs and other ungulate species: an alternative to embryonic stem cells? *Reproduction in domestic animals = Zuchthygiene*. 2012;47 Suppl 4:92-97.
61. Koh S, Piedrahita JA. From "ES-like" cells to induced pluripotent stem cells: a historical perspective in domestic animals. *Theriogenology*. 2014;81(1):103-111.
62. Huang B, Li T, Alonso-Gonzalez L, Gorre R, Keatley S, Green A, et al. A virus-free poly-promoter vector induces pluripotency in quiescent bovine cells under chemically defined conditions of dual kinase inhibition. *PloS one*. 2011;6(9):e24501.
63. Wang SW, Wang SS, Wu DC, Lin YC, Ku CC, Wu CC, et al. Androgen receptor-mediated apoptosis in bovine testicular induced pluripotent stem cells in response to phthalate esters. *Cell death & disease* 2013;4: e907.
64. Lin YC, Kuo KK, Wuputra K, Lin SH, Ku CC, Yang YH, et al. Bovine induced pluripotent stem cells are more resistant to apoptosis than testicular cells in response to mono-(2-ethylhexyl) phthalate. *International journal of molecular sciences*. 2014;15(3):5011-5031. doi:10.3390/ijms15035011
65. Talluri TR, Kumar D, Glage S, Garrels W, Ivics Z, Debowski K, et al. Derivation and characterization of bovine induced pluripotent stem cells by transposon-mediated reprogramming. *Cellular reprogramming*. 2015;17(2):131-40.
66. Zhao L, Wang Z, Zhang J, Yang J, Gao X, Wu B, et al. Characterization of the single-cell derived bovine induced pluripotent stem cells. *Tissue & cell*. 2017;49(5):521-527.
67. Heo YT, Quan X, Xu YN, Baek S, Choi H, Kim NH, et al. CRISPR/Cas9 nuclease-mediated gene knock-in in bovine-induced pluripotent cells. *Stem cells and development*. 2015;24(3):393-402.
68. Malaver-Ortega LF, Sumer H, Liu J, Verma PJ. Inhibition of JAK-STAT ERK/MAPK and Glycogen Synthase Kinase-3 Induces a Change in Gene Expression Profile of Bovine Induced Pluripotent Stem Cells. *Stem cells international* 2016. 2016:5127984.
69. Moon SY, Eun HJ, Baek SK, Jin SJ, Kim TS, Kim, SW, et al. Activation-Induced Cytidine Deaminase Induces DNA Demethylation of Pluripotency Genes in Bovine Differentiated Cells. *Cellular reprogramming*. 2016;18(5):298-308.
70. Schlaeger TM, Daheron L, Brickler TR, Entwisle S, Chan K, Cianci A, et al. A comparison of non-integrating reprogramming methods. *Nature biotechnology*. 2015;33(1):58-63.
71. Yoshioka N, Gros E, Li HR, Kumar S, Deacon DC, Maron C, et al. Efficient generation of human iPSCs by a synthetic self-replicative RNA. *Cell stem cell*. 2013;13(2):246-254.
72. Zhu S, Li W, Zhou H, Wei W, Ambasadhan R, Lin T, et al. Reprogramming of human primary somatic cells by OCT4 and chemical compounds. *Cell stem cell*. 2010;7(6):651-655. doi: 10.1016/j.stem.2010.11.015
73. Li Y, Zhang Q, Yin X, Yang W, Du Y, Hou P, et al. Generation of iPSCs from mouse fibroblasts with a single gene, Oct4, and small molecules. *Cell research*. 2011;21(1):196-204.
74. Hou P, Li Y, Zhang X, Liu C, Guan J, Li H, et al. Pluripotent stem cells induced from mouse somatic cells by small-molecule compounds. *Science (New York, N.Y.)*. 2013;341(6146):651-654. doi: 10.1126/science.1239278
75. Du X, Feng T, Yu D, Wu Y, Zou H, Ma S, et al. Barriers for Deriving Transgene-Free Pig iPS Cells with Episomal Vectors. *Stem cells (Dayton, Ohio)*. 2015;33(11):3228-3238.
76. Steinert AF, Palmer GD, Pilapil C, Noth U, Evans CH, Ghivizzani SC. Enhanced in vitro chondrogenesis of primary mesenchymal stem cells by combined gene transfer. *Tissue engineering. Part A*. 2009;15(5):1127-1139.
77. Khan IM, Bishop JC, Gilbert, S, Archer CW. Clonal chondroprogenitors maintain telomerase activity and Sox9 expression during extended monolayer culture and retain chondrogenic potential. *Osteoarthritis and cartilage*. 2009;17(4):518-528.
78. Angele P, Schumann D, Angele M, Kinner B, Englert C, Hente R, et al. Cyclic, mechanical compression enhances chondrogenesis of mesenchymal progenitor cells in tissue engineering scaffolds. *Biorheology* 2004;41 (3-4):335-346.
79. Huang, CY, Hagar KL, Frost LE, Sun Y, Cheung HS. Effects of cyclic compressive loading on chondrogenesis of rabbit bone-marrow derived mesenchymal stem cells. *Stem cells (Dayton, Ohio)*. 2004;22(3):313-323.
80. Allon AA, Butcher K, Schneider RA, Lotz JC. Structured bilaminar coculture outperforms stem cells and disc cells in a simulated degenerate disc environment. *Spine*. 2012;37(10):813-818. doi: 10.1097/BRS.0b013e31823b055f

81. Lai JH, Kajiyama G, Smith RL, Maloney W, Yang F. Stem cells catalyze cartilage formation by neonatal articular chondrocytes in 3D biomimetic hydrogels. *Scientific reports*. 2013;3:3553.
82. Martignani E, Eirew P, Accornero P, Eaves CJ, Baratta M. Human milk protein production in xenografts of genetically engineered bovine mammary epithelial stem cells. *PloS one* 2010;5(10):e13372.
83. Rauner G, Barash I. Xanthosine administration does not affect the proportion of epithelial stem cells in bovine mammary tissue, but has a latent negative effect on cell proliferation. *Experimental cell research*. 2014;328(1):186-196.
84. Shuster DE, Kehrl ME Jr, Ackermann MR, Gilbert RO. Identification and prevalence of a genetic defect that causes leukocyte adhesion deficiency in Holstein cattle. *Proceedings of the National Academy of Sciences of the United States of America* 1992;89(19):9225-9229.
85. Nagahata H, Matsuki S, Higuchi H, Inanami O, Kuwabara M, Kobayashi, K. Bone marrow transplantation in a Holstein heifer with bovine leucocyte adhesion deficiency. *Veterinary journal (London, England : 1997)*.1998;156(1):15-21.
86. Nagahata H, Hagiwara K, Higuchi H, Kirisawa R, Iwai H. Analysis of serum cytokine profile in a holstein heifer with leukocyte adhesion deficiency which survived for long period. *The Journal of veterinary medical science*. 2002;64(8):683-687.
87. Shiflett SL, Kaplan J, Ward DM. Chediak-Higashi Syndrome: a rare disorder of lysosomes and lysosome related organelles. *Pigment cell research*. 2002;15(4):251-257.
88. Ogawa H, Tu CH, Kagamizono H, Soki K, Inoue Y, Akatsuka H, et al. Clinical, morphologic, and biochemical characteristics of Chediak-Higashi syndrome in fifty-six Japanese black cattle. *American journal of veterinary research*. 1997;58 (11):1221-1226.
89. Shiraishi M, Ogawa H, Ikeda M, Kawashima S, Ito K. Platelet dysfunction in Chediak-Higashi syndrome-affected cattle. *The Journal of veterinary medical science*.2002;64(9):751-60.
90. Ayers J R, Leipold HW, Padgett GA. Lesions in Brangus cattle with Chediak-Higashi syndrome. *Veterinary pathology*.1988;25 (6):432-436.